The debate highlighted that G2019S shows elevated baseline RAB10 phosphorylation, but it's unclear whether this represents true signal amplification during lysosomal swelling or just a higher activity floor. This distinction is crucial for understanding disease mechanisms and therapeutic targeting.
Source: Debate session sess_SDA-2026-04-16-gap-pubmed-20260410-170027-a1e5f867_20260416-135352 (Analysis: SDA-2026-04-16-gap-pubmed-20260410-170027-a1e5f867)
G2019S specifically hyperactivates LRRK2 when recruited to swelling lysosomes via RAB29, creating pathogenic positive feedback where membrane stress increases RAB10 phosphorylation more than wild-type. Key experimental prediction: rise kinetics (slope) should differ between G2019S and WT, not merely baseline offset. RAB29 pathogenic mutations (PARK23) confirm disease relevance of this axis.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["LRRK2 G2019S Gain of Function"]
B["RAB29 Recruitment to Lysosomal Membrane"]
C["Enhanced Lysosomal Volume Sensing"]
D["Signal Amplification Pathological Threshold"]
E["Lysosomal Dysfunction Autophagy Impairment"]
F["Neuronal Death PD Progression"]
G["RAB29 as Modifier of LRRK2 Pathogenesis"]
A --> B
B --> C
C --> D
D --> E
E --> F
A --> G
G --> C
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
5 citations5 with PMIDValidation: 0%3 supporting / 2 opposing
✓For(3)
No supporting evidence
No opposing evidence
(2)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
4
1
MECH 4CLIN 0GENE 1EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
RAB29 pathogenic mutations (PARK23) cause early-on…
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-26 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Therapeutic/Mechanistic Hypotheses Addressing LRRK2 Signal Amplification vs. Baseline Elevation
Hypothesis 1: G2019S Acts as a Lysosomal Volume-Sensing Amplifier via Enhanced RAB29-Dependent Recruitment
Mechanism: G2019S specifically hyperactivates LRRK2 when recruited to swelling lysosomes via RAB29, creating a pathogenic positive feedback loop where membrane stress increases RAB10 phosphorylation more than wild-type.
Target Gene/Protein: LRRK2 (G2019S) + RAB29 axis
Supporting Evidence:
RAB29 pathogenic mutations (PARK23) cause early-onset Parkinsonism (PMID: 28165
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Critical Evaluation of LRRK2 Hypotheses
Overview
The core question—whether G2019S increases signal amplification during lysosomal swelling versus merely elevating the baseline activity floor—requires distinguishing between these mechanistically distinct possibilities. Most hypotheses conflate these, and none provide decisive evidence for either model.
Hypothesis 1: Lysosomal Volume-Sensing Amplifier via RAB29
Weak Links
Recruitment enhancement not demonstrated: The cited PMIDs establish that RAB29 recruits LRRK2 to stressed lysosomes, but do not show G2019S specifica
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Feasibility Assessment: LRRK2 G2019S Signal Amplification vs. Baseline Elevation Hypotheses
Executive Summary
The core mechanistic question—whether LRRK2 G2019S drives pathology through amplified signaling during lysosomal stress versus simply elevating the basal activity floor—carries significant therapeutic implications. If amplification is pathogenic, partial kinase inhibition strategies become rational; if elevated baseline alone drives neurodegeneration, complete inhibition may be required. This distinction will shape trial design, dose selection, and acceptable safety profiles.
B
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
IF primary cortical neurons from G2019S LRRK2 knock-in mice are treated with nigericin (1 µM) to induce lysosomal swelling, THEN the initial rate (slope, 0-30 min) of RAB10 phosphorylation at Thr72 will increase significantly more (>50% steeper) compared to WT neurons, as measured by quantitative phospho-western blot with time-course sampling every 10 minutes.
pendingconf: 0.78
Expected outcome: G2019S neurons show a significantly steeper rise in RAB10-pThr72 signal over the first 30 minutes of lysosomal swelling compared to WT neurons, with the slope difference exceeding 50%.
Falsified by: If the kinetic slope (rate of RAB10 phosphorylation increase) is not significantly different between G2019S and WT neurons (95% CI overlap) OR if only baseline/offset differences exist without slope differences, the hypothesis is falsified.
Method: Primary cortical neurons from G2019S LRRK2 KI mice (Jackson Labs) vs age-matched WT littermates, treated with nigericin (1 µM) to model lysosomal swelling, with quantitative phospho-western blot sampling at t=0, 10, 20, 30, 60 min. RAB10-pThr72 signal normalized to total RAB10 and GAPDH loading control. Linear regression analysis of initial rate.
IF RAB29 is knocked out via CRISPR-Cas9 in G2019S LRRK2 KI neurons, THEN the amplified RAB10 phosphorylation slope observed under nigericin-induced lysosomal swelling will be abolished, reducing the kinetic difference to <15% compared to WT+RAB29-KO neurons.
pendingconf: 0.72
Expected outcome: RAB29 knockout eliminates the G2019S-specific enhancement of RAB10 phosphorylation kinetics, resulting in no significant slope difference between G2019S/RAB29-KO and WT/RAB29-KO under lysosomal stress.
Falsified by: If G2019S/RAB29-KO neurons retain significantly steeper RAB10 phosphorylation slopes (>30% difference) compared to WT/RAB29-KO under lysosomal swelling, the RAB29-dependence of the amplification mechanism is falsified.
Method: CRISPR-Cas9 ribonucleoprotein delivery (Electroporation) targeting RAB29 exon 1 in primary cortical neurons from G2019S KI and WT mice. Validation of RAB29 knockout by immunofluorescence (>90% knockout efficiency) and western blot. RAB10-pThr72 kinetics measured as in Prediction 1. Four experimental groups: G2019S+RAB29-WT, G2019S+RAB29-KO, WT+RAB29-WT, WT+RAB29-KO.